Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ERK1/2 pro-survival signalling is suppressed by pirtobrutinib in ibrutinib-resistant MYD88-mutated lymphoma cells.
Munshi M, Liu X, Kofides A, Tsakmaklis N, Hunter ZR, Guerrera ML, Canning A, Gustine JN, Liu S, Hatcher JM, Chen J, Meid K, Sarosiek S, Flynn CA, Branagan AR, von Keudell G, Palomba LM, Castillo JJ, Yang G, Treon SP. Munshi M, et al. Among authors: tsakmaklis n. Br J Haematol. 2024 Sep 18. doi: 10.1111/bjh.19756. Online ahead of print. Br J Haematol. 2024. PMID: 39295138
Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia.
Richardson K, Castillo JJ, Sarosiek SR, Branagan AR, Flynn CA, Meid K, Gustine JN, Liu X, Kofides A, Liu S, Wolf JL, Kacena KA, Patterson CJ, Guerrera ML, Tsakmaklis N, Treon SP, Hunter ZR. Richardson K, et al. Among authors: tsakmaklis n. Blood Adv. 2024 May 14;8(9):2133-2137. doi: 10.1182/bloodadvances.2023012111. Blood Adv. 2024. PMID: 38237078 Free PMC article. No abstract available.
Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.
Castillo JJ, Branagan AR, Sermer D, Flynn CA, Meid K, Little M, Stockman K, White T, Canning A, Guerrera ML, Kofides A, Liu S, Liu X, Richardson K, Tsakmaklis N, Patterson CJ, Hunter ZR, Treon SP, Sarosiek S. Castillo JJ, et al. Among authors: tsakmaklis n. Blood. 2024 Feb 15;143(7):582-591. doi: 10.1182/blood.2023022420. Blood. 2024. PMID: 37971194 Free PMC article.
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.
Munshi M, Liu X, Kofides A, Tsakmaklis N, Guerrera ML, Hunter ZR, Palomba ML, Argyropoulos KV, Patterson CJ, Canning AG, Meid K, Gustine J, Branagan AR, Flynn CA, Sarosiek S, Castillo JJ, Wang J, Buhrlage SJ, Gray NS, Munshi NC, Anderson KC, Treon SP, Yang G. Munshi M, et al. Among authors: tsakmaklis n. Blood Adv. 2022 Jun 14;6(11):3332-3338. doi: 10.1182/bloodadvances.2021006147. Blood Adv. 2022. PMID: 35255496 Free PMC article.
Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy.
Castillo JJ, Sarosiek SR, Gustine JN, Flynn CA, Leventoff CR, White TP, Meid K, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Hunter ZR, Patterson CJ, Branagan AR, Treon SP. Castillo JJ, et al. Among authors: tsakmaklis n. Blood Adv. 2022 Feb 8;6(3):1015-1024. doi: 10.1182/bloodadvances.2021006106. Blood Adv. 2022. PMID: 34965304 Free PMC article.
Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Furman RR, Treon SP. Castillo JJ, et al. Among authors: tsakmaklis n. J Clin Oncol. 2022 Jan 1;40(1):63-71. doi: 10.1200/JCO.21.01194. Epub 2021 Nov 18. J Clin Oncol. 2022. PMID: 34793256 Free PMC article. Clinical Trial.
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia.
Castillo JJ, Meid K, Gustine JN, Leventoff C, White T, Flynn CA, Sarosiek S, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Branagan AR, O'Donnell E, Raje N, Yee AJ, Patterson CJ, Hunter ZR, Treon SP. Castillo JJ, et al. Among authors: tsakmaklis n. Leukemia. 2022 Feb;36(2):532-539. doi: 10.1038/s41375-021-01417-9. Epub 2021 Sep 16. Leukemia. 2022. PMID: 34531537 Free PMC article.
Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia.
Kofides A, Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Munshi M, Liu X, Guerrera ML, Leventoff CR, White TP, Flynn CA, Meid K, Patterson CJ, Yang G, Branagan AR, Sarosiek S, Castillo JJ, Treon SP, Gustine JN. Kofides A, et al. Among authors: tsakmaklis n. Hemasphere. 2021 Jul 19;5(8):e624. doi: 10.1097/HS9.0000000000000624. eCollection 2021 Aug. Hemasphere. 2021. PMID: 34291197 Free PMC article. No abstract available.
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
Treon SP, Meid K, Hunter ZR, Flynn CA, Sarosiek SR, Leventoff CR, White TP, Cao Y, Roccaro AM, Sacco A, Demos MG, Guerrera ML, Kofides A, Liu X, Xu L, Patterson CJ, Munshi M, Tsakmaklis N, Yang G, Ghobrial IM, Branagan AR, Castillo JJ. Treon SP, et al. Among authors: tsakmaklis n. Blood. 2021 Oct 28;138(17):1535-1539. doi: 10.1182/blood.2021012953. Blood. 2021. PMID: 34289017 Free PMC article. Clinical Trial.
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.
Gustine JN, Sarosiek S, Flynn CA, Meid K, Leventoff C, White T, Guerrera ML, Xu L, Kofides A, Tsakmaklis N, Munshi M, Demos M, Patterson CJ, Liu X, Yang G, Hunter ZR, Branagan AR, Treon SP, Castillo JJ. Gustine JN, et al. Among authors: tsakmaklis n. Haematologica. 2022 May 1;107(5):1163-1171. doi: 10.3324/haematol.2021.279112. Haematologica. 2022. PMID: 34162182 Free PMC article.
42 results